Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating Cardiff Oncology's Onvansertib as a therapy for pancreatic cancer

Ticker(s): CRDF

Who's the expert?

An oncologist with experience treating patients for pancreatic cancer.

Interview Goal

This call will include a discussion on the current standard of care and the potential of Onvansertib, a PLK inhibitor being developed by Cardiff Oncology for the treatment of pancreatic cancer. The conversation will also include a look at the data released from the ongoing phase 2 trials on onvansertib as a monotherapy and combination therapy for metastatic pancreatic ductal adenocarcinoma.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.